BOSTON --(BUSINESS WIRE)--Mar. 26, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

Met primary endpoint in Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and demonstrated favorable safety profile with no significant weight gain, somnolence or extrapyramidal side effects relative to placebo Met secondary endpoints on both PANSS

BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

Announces new strategic drug discovery partnership with Charles River Opens new office dedicated to drug discovery and potential development of novel CNS therapeutics BOSTON --(BUSINESS WIRE)--Feb. 6, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company

BOSTON --(BUSINESS WIRE)--Jan. 9, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today